RecruitingPhase 2NCT05050136

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Studying Primary biliary cholangitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Mirum Pharmaceuticals, Inc.
Intervention: Volixibat(drug)
Enrollment: 260 target
Eligibility: 18 years · All sexes
Timeline: 2021 – 2027

Study locations (30)

Southern California Research Center, Coronado, California, United States
Cedars Sinai Medical Center, Los Angeles, California, United States
UC Davis, Sacramento, California, United States
University of Colorado, Aurora, Colorado, United States
Yale University Digestive Diseases, New Haven, Connecticut, United States
Covenant Metabolic Specialists, Fort Myers, Florida, United States
UF Hepatology Research at CTRB, Gainesville, Florida, United States
UF Health Gastroenterology- Emerson, Jacksonville, Florida, United States
IHS Health, Kissimmee, Florida, United States
Schiff Center for Liver Diseases, Miami, Florida, United States
Advanced Research Institute, Inc, New Port Richey, Florida, United States
Covenant Research and Clinics, LLC, Sarasota, Florida, United States
Tampa General Hospital, Tampa, Florida, United States
Cleveland Clinic Florida, Weston, Florida, United States
Southeast Clinical Research Center, Dalton, Georgia, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05050136 on ClinicalTrials.gov

Other trials for Primary biliary cholangitis

Additional recruiting or active studies for the same condition.

See all trials for Primary biliary cholangitis →

← Back to all trials